Basilea awarded additional USD 4 3 million by BARDA to globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
One year after the explosion disaster - Beirut and Lebanon between crisis and reconstruction
Format
On 4 August 2020, 2750 tons of ammonium nitrate exploded in the port of Beirut. A huge shock wave hit large parts of the city. Pictures of the destruction went around the world. More than 200 people lost their lives, over 6000 were injured. Hundreds of thousands had to leave their destroyed or collapsed houses. One year later, reconstruction is in full swing. KfW is also stepping up its commitment with funds from the Federal Ministry for Economic Cooperation and Development (BMZ).
Sascha Stadtler, head of KfW s Beirut office, reports: The situation of many people suddenly deteriorated once again on 4 August. Even before the explosion, Lebanon faced enormous challenges. The country was in the middle of one of the worst economic and financial crises of the last 150 years. Unemployment and national debt were crushingly high. In addition, more than one million refugees had sought shelt
Basel, Switzerland, July 29, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basilea’s tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer). This includes glioblastoma, the most common type of primary brain cancer and one of the most lethal types of cancer.
1 Orphan Drug Designation qualifies the sponsor of the drug for various incentives, including longer regulatory market exclusivity.
Dr. Marc Engelhardt, Chief Medical Officer, commented: “The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin. Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available. Lisavanbulin, as a targeted treatment, could be a useful new approach to expand the treatment options for patients with this devastating disease.”
(1)
Basel, Switzerland, July 29, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basilea s tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer). This includes glioblastoma, the most common type of primary brain cancer and one of the most lethal types of cancer.
1 Orphan Drug Designation qualifies the sponsor of the drug for various incentives, including longer regulatory market exclusivity.
Dr. Marc Engelhardt, Chief Medical Officer, commented: The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin. Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available. Lisavanbulin, as a targeted treatment, could be a useful new approach to expand the treatment options for patients with this devastating disease.